To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL wit…

BlinatumomabRevumenibLymphoblastic Leukemia+1 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07283640

Phase 1

A Phase 1 Study of Menin-KMT2A Inhibitor Ziftomenib (KO-539) in Combination With Cereblon E3 Ligase Modulator Mezigdomide (CC-92480) in Adolescents and Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with ei…

KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML

~Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07355335